
Artivion (AORT) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
99.0M
Gross Profit
63.6M
64.23%
Operating Income
2.1M
2.17%
Net Income
-505.0K
-0.51%
EPS (Diluted)
$-0.01
Balance Sheet Metrics
Total Assets
787.0M
Total Liabilities
496.9M
Shareholders Equity
294.3M
Debt to Equity
1.69
Cash Flow Metrics
Operating Cash Flow
-17.9M
Free Cash Flow
-20.6M
Revenue & Profitability Trend
Artivion Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 388.5M | 354.0M | 313.8M | 298.8M | 253.2M |
Cost of Goods Sold | 139.8M | 124.8M | 111.3M | 101.3M | 85.4M |
Gross Profit | 248.8M | 229.2M | 202.5M | 197.5M | 167.8M |
Gross Margin % | 64.0% | 64.7% | 64.5% | 66.1% | 66.3% |
Operating Expenses | |||||
Research & Development | 28.5M | 28.7M | 38.9M | 35.5M | 24.2M |
Selling, General & Administrative | 181.5M | 209.0M | 157.4M | 169.8M | 141.1M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 209.9M | 237.7M | 196.3M | 205.3M | 165.3M |
Operating Income | 38.9M | -8.5M | 6.2M | -7.8M | 2.4M |
Operating Margin % | 10.0% | -2.4% | 2.0% | -2.6% | 1.0% |
Non-Operating Items | |||||
Interest Income | 1.5M | 1.1M | 147.0K | 79.0K | 217.0K |
Interest Expense | 34.3M | 25.3M | 18.2M | 16.9M | 16.7M |
Other Non-Operating Income | -13.6M | 11.1M | -3.1M | 9.8M | -3.1M |
Pre-tax Income | -7.5M | -21.6M | -15.0M | -14.8M | -17.2M |
Income Tax | 5.8M | 9.1M | 4.2M | 7.0K | -492.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -13.4M | -30.7M | -19.2M | -14.8M | -16.7M |
Net Margin % | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% |
Key Metrics | |||||
EBITDA | 54.6M | 12.5M | 25.7M | 10.1M | 20.2M |
EPS (Basic) | - | $-0.75 | $-0.48 | $-0.38 | $-0.44 |
EPS (Diluted) | - | $-0.75 | $-0.48 | $-0.38 | $-0.44 |
Basic Shares Outstanding | - | 40743000 | 40032000 | 38983000 | 37861000 |
Diluted Shares Outstanding | - | 40743000 | 40032000 | 38983000 | 37861000 |
Income Statement Trend
Artivion Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 53.5M | 58.9M | 39.4M | 55.0M | 61.4M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 79.5M | 71.8M | 61.8M | 53.0M | 46.0M |
Inventory | 79.8M | 82.0M | 74.5M | 77.0M | 73.0M |
Other Current Assets | 19.3M | 15.8M | 17.6M | 14.7M | - |
Total Current Assets | 290.1M | 280.7M | 247.3M | 247.7M | 234.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | 39.7M | 43.8M | 41.9M | 58.1M | 28.2M |
Goodwill | 638.3M | 666.9M | 669.9M | 701.5M | 747.2M |
Intangible Assets | 156.4M | 172.2M | 182.6M | 201.5M | 227.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 25.6M | 10.0M | 8.7M | 10.6M | 16.0M |
Total Non-Current Assets | 499.0M | 511.7M | 515.5M | 545.4M | 554.8M |
Total Assets | 789.1M | 792.4M | 762.8M | 793.1M | 789.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 18.0M | 13.3M | 12.0M | 10.4M | 9.6M |
Short-term Debt | 5.3M | 5.4M | 5.4M | 5.3M | 7.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 583.0K | 2.4M | 1.3M | 1.1M | 19.2M |
Total Current Liabilities | 66.8M | 57.9M | 49.7M | 45.0M | 60.5M |
Non-Current Liabilities | |||||
Long-term Debt | 357.0M | 352.9M | 351.4M | 356.7M | 309.8M |
Deferred Tax Liabilities | 20.2M | 21.9M | 24.5M | 28.8M | 34.7M |
Other Non-Current Liabilities | 60.9M | 71.2M | 47.4M | 55.9M | 50.2M |
Total Non-Current Liabilities | 446.1M | 452.8M | 428.8M | 447.4M | 400.2M |
Total Liabilities | 512.9M | 510.6M | 478.5M | 492.3M | 460.7M |
Equity | |||||
Common Stock | 434.0K | 426.0K | 418.0K | 414.0K | 404.0K |
Retained Earnings | -61.3M | -47.9M | -17.2M | 2.0M | 20.0M |
Treasury Stock | 14.6M | 14.6M | 14.6M | 14.6M | 14.6M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 276.2M | 281.8M | 284.3M | 300.7M | 328.7M |
Key Metrics | |||||
Total Debt | 362.3M | 358.3M | 356.8M | 362.0M | 317.4M |
Working Capital | 223.3M | 222.8M | 197.7M | 202.7M | 174.1M |
Balance Sheet Composition
Artivion Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -13.4M | -30.7M | -19.2M | -14.8M | -16.7M |
Depreciation & Amortization | 24.2M | 23.1M | 22.4M | 24.0M | 20.7M |
Stock-Based Compensation | 14.2M | 14.4M | 12.3M | 10.7M | 6.9M |
Working Capital Changes | -12.0M | -16.7M | -23.7M | -31.8M | -24.0M |
Operating Cash Flow | 19.3M | 27.8M | -7.3M | 4.4M | 11.6M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | -5.0M | 0 | 0 | -64.1M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | 0 | 19.0M | - |
Investing Cash Flow | -17.0M | 6.9M | -1.7M | 19.7M | -65.8M |
Financing Activities | |||||
Share Repurchases | 0 | -559.0K | -1.8M | -1.9M | -2.0M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 212.5M | - | 0 | 0 | 100.0M |
Debt Repayment | -212.9M | -5.3M | -2.8M | -3.1M | -35.3M |
Financing Cash Flow | -4.6M | -5.6M | -5.0M | -16.0M | 61.2M |
Free Cash Flow | 11.0M | 11.4M | -14.2M | -16.6M | 5.0M |
Net Change in Cash | -2.2M | 29.1M | -14.0M | 8.2M | 7.0M |
Cash Flow Trend
Artivion Key Financial Ratios
Valuation Ratios
Forward P/E
170.63
Price to Book
4.59
Price to Sales
4.76
PEG Ratio
170.63
Profitability Ratios
Profit Margin
-4.43%
Operating Margin
9.72%
Return on Equity
-5.02%
Return on Assets
1.70%
Financial Health
Current Ratio
4.78
Debt to Equity
62.81
Beta
1.64
Per Share Data
EPS (TTM)
$-0.43
Book Value per Share
$8.91
Revenue per Share
$9.52
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
aort | 1.9B | - | 4.59 | -5.02% | -4.43% | 62.81 |
Abbott Laboratories | 233.7B | 16.83 | 4.62 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 152.8B | 61.39 | 6.81 | 11.55% | 13.55% | 53.09 |
Conmed | 1.7B | 15.44 | 1.69 | 11.69% | 8.31% | 87.93 |
Enovis | 1.6B | -1.90 | 0.63 | -28.25% | -37.80% | 56.75 |
QuidelOrtho | 1.6B | -0.78 | 0.58 | -15.64% | -17.01% | 100.33 |
Financial data is updated regularly. All figures are in the company's reporting currency.